Program
conestat alfa
Also written as “Ruconest”, “Recombinant Human C1 Inhibitor” and “rhC1INH”.
Its studies are mostly in Angioedemas, Hereditary · COVID-19 · Fatigue Syndrome, Chronic, led by 2 companies.
Drug pageConestat alfa: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pharming Groupits history only | 60 open or running | phase 3since Sep 20, 2005 | Sep 20, 2005 | none ahead |
| IMMUNOe Research Centers | 21 open or running | phase 4since Nov 6, 2026 | Jan 7, 2021 | Jul 31, 2027phase 4 · NCT07932002 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of IMMUNOe Research Centers only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 7, 2021First study: phase 2 study in Fatigue Syndrome, ChronicFirst studyNCT04705831 · 40 enrolled · United States
- Nov 6, 2026Phase 4 study in COVID-19NCT07932002 · 30 planned · United States
Ahead
- Jul 31, 2027Primary completion: phase 4 study in COVID-19NCT07932002
TargetBeta
“A recombinant form of human complement component 1 esterase inhibitor (C1INH), a serine protease inhibitor normally present in human plasma, that can be used for the treatment of hereditary angioedema (HAE)”NCIt, by rule
“Plasma protease C1 inhibitor exogenous protein”ChEMBL 37, by rule
Studies
All 2 IMMUNOe Research Centers leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07932002COVID-19 · United States | 4 | Recruiting | Jul 31, 2027 | 30 |
| NCT04705831Fatigue Syndrome, Chronic · United States | 2 | Completed | Mar 30, 2024 | 40 |
How it is read
Names in the registry
- “Ruconest”, 3 entries
- “Recombinant Human C1 Inhibitor”, 2 entries
- “rhC1INH”, 1 entry
- “Recombinant human C1 inhibitor”, 1 entry
- “recombinant human C1 inhibitor”, 1 entry
Conditions, from the studies’ own filings
- Angioedemas, Hereditary, 5 studies
- COVID-19, 1 study
- Fatigue Syndrome, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.